Piotr Wysocki recently shared on LinkedIn:

“In many countries, the availability of checkpoint inhibitors-based immunotherapy is limited or even does not exist. Especially in the case of rare tumors such as cutaneous squamous cell cancer (SCC), for many patients around the world, novel, active drugs are entirely unavailable.

Here we present a case of a patient with critically advanced skin SCC who achieved a complete, long-term response to a skilfully optimized metronomic chemotherapy. This case confirms that a good understanding of disease properties and biological features allows for an optimal combination of cheap, cytotoxic drugs, which may lead to a profound clinical benefit.”

Strikingly high activity of metronomic chemotherapy in a patient with locally advanced, life-threatening cutaneous squamous-cell cancer — case report and discussion of the literature

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.

Read other posts by Piotr Wysocki published on OncoDaily.